SCHEDULE 13G/A: T. Rowe Price Investment Management Discloses 14.1% Stake in Immunocore Holdings PLC-ADR
Beneficial Ownership Report (Schedule 13G Amendment)
T. Rowe Price Investment Management, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 14.1% in Immunocore Holdings PLC-ADR as of March 31, 2025.
Summary
- T. Rowe Price Investment Management, Inc. filed an Amendment No. 2 to Schedule 13G regarding its beneficial ownership in IMMUNOCORE HOLDINGS PLC-ADR.
- As of March 31, 2025, T. Rowe Price Investment Management, Inc. beneficially owns an aggregate of 7,051,818 shares of Immunocore Holdings PLC-ADR.
- This ownership represents 14.1% of the class of securities.
- T. Rowe Price Investment Management, Inc. holds sole voting power and sole dispositive power over all 7,051,818 shares.
- The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, providing neutral information without explicit positive or negative performance indicators for the issuer. The sentiment is based on the objective reporting of an institutional investment.
Positives
- A significant stake (14.1%) held by a reputable investment firm like T. Rowe Price Investment Management, Inc. may signal confidence in Immunocore Holdings PLC-ADR's long-term prospects.
- The investment is stated to be in the ordinary course of business, indicating a standard portfolio allocation rather than an activist intent.
Risks
- The filing explicitly states that T. Rowe Price Investment Management, Inc. denies beneficial ownership of the securities, despite the filing, which is a standard legal disclaimer.
Future Outlook
This document does not contain any forward-looking statements or guidance regarding Immunocore Holdings PLC-ADR's future performance or T. Rowe Price's future investment intentions beyond the current ownership disclosure.
Industry Context
Immunocore Holdings PLC-ADR operates in the biotechnology or pharmaceutical sector, given its name and the nature of its securities (ADRs). T. Rowe Price Investment Management, Inc. is a major global asset manager, and its significant stake in a company like Immunocore reflects its investment strategy within the healthcare or life sciences industry. Such filings are common for large institutional investors disclosing their positions in publicly traded companies.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by a major institutional investor like T. Rowe Price may be viewed positively, potentially signaling institutional confidence and stability in the stock.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires filing of this statement (reporting period end date). |
| 05/14/2025 | Date the Schedule 13G Amendment No. 2 was signed by T. Rowe Price Investment Management, Inc. |
Keywords
Immunocore Holdings PLC-ADR, T. Rowe Price Investment Management, Schedule 13G, Beneficial Ownership, Investment Adviser, ADR, Biotechnology, Pharmaceuticals, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.